[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"common-wart\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:common-wart":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,57,84],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":21,"briefSummary":23,"conditions":24,"keywords":33,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":45,"lastUpdatePostDateStruct":46,"startDateStruct":49,"completionDateStruct":51,"leadSponsor":53,"locationsCount":56},"100627454","phase-4-intralesional-therapies-for-cutaneous-viral-warts-a-comparative-analysis-of-vitamin-d3-and-acyclovir-100627454",false,"NCT07448844","Intralesional Therapies For Cutaneous Viral Warts: A Comparative Analysis Of Vitamin D3 And Acyclovir","Inclusion Criteria:\n\n* Patients aged 12 years and above with clinically diagnosed cutaneous warts\n* Common, plantar, flat, or periungual warts\n* Both treatment-naïve patients and those with recalcitrant warts\n\nExclusion Criteria:\n\n* Pregnant or lactating women\n* Immunocompromised patients\n* Individuals with history of hypersensitivity to vitamin D3 or acyclovir\n* Individuals receiving systemic immunosuppressive or antiviral therapy\n* Patients with secondary infection at injection site\n* Patients who had received any topical or destructive treatment for wart in previous three months","ALL","12 Years",{"count":18,"type":19},40,"ESTIMATED","INTERVENTIONAL",[22],"PHASE4","The goal of this clinical trial is to learn if injecting acyclovir (an antiviral drug) or vitamin D3 directly into skin warts works to clear them in people aged 12 and older with common, plantar, flat, or periungual (around the nail) warts. The main questions it aims to answer are:\n\n1. Does intralesional acyclovir or vitamin D3 lead to complete clearance of warts by week 8?\n2. Which treatment clears warts more effectively?\n3. What side effects do participants have with each treatment?\n\nResearchers will compare acyclovir injections (Group A) to vitamin D3 injections (Group B), with 20 participants in each group, to see which treatment works better at clearing warts.\n\nParticipants will:\n\n1. Receive an injection directly into the wart every 2 weeks for up to 4 sessions\n2. Have photographs taken of their warts before treatment and at each visit\n3. Visit the clinic for checkups where the size and number of warts will be measured\n4. Be followed for up to 3 months to check for wart recurrence and side effects",[25,26,27,28,29,30,31,32],"Viral Wart","Plantar Wart","Common Warts (Verruca Vulgaris)","Common Wart","Flat Wart","Warts of Foot","Warts Hand","Wart",[34,35,36,37,38,39,40,41,42,43],"Cutaneous warts","intralesional therapy","treatment efficacy","plantar warts","common warts","human papillomavirus","randomized controlled trial","vitamin D3","acyclovir","flat warts","RECRUITING","2026-03-06",{"date":47,"type":48},"2026-03-10","ACTUAL",{"date":50,"type":48},"2026-02-20",{"date":52,"type":19},"2026-05-20",{"name":54,"class":55},"Riphah International University","OTHER",2,{"id":58,"slug":59,"hasResults":11,"nctId":60,"briefTitle":61,"officialTitle":62,"acronym":4,"eligibilityCriteria":63,"healthyVolunteers":64,"sex":15,"minAge":65,"maxAge":66,"enrollmentInfo":67,"targetDuration":4,"studyType":20,"phases":69,"briefSummary":71,"conditions":72,"keywords":4,"overallStatus":73,"whyStopped":4,"lastUpdateSubmitDate":74,"lastUpdatePostDateStruct":75,"startDateStruct":77,"completionDateStruct":79,"leadSponsor":81,"locationsCount":83},"100573698","sclerotherapy-and-candida-antigen-in-treatment-of-common-warts-100573698","NCT06749665","Sclerotherapy and Candida Antigen in Treatment of Common Warts","Efficacy and Safety of Intralesional Injections of Candida Antigen, Polidocanol Sclerotherapy and Combined Candida Antigen With Polidocanol in Treatment of Patients With Common Warts","Inclusion Criteria:\n\n* Age group: \\>18years.\n* Confirmed diagnosis by clinical and dermoscopic examination of common wart will be made.\n\nExclusion Criteria:\n\n* Patients who receive any treatment for wart in the last month before the study.\n* Patients with history of renal or liver disease.\n* Patients with any evidence of bleeding diathesis, vaso-occulusive or thrombo-embolic disorders.\n* Pregnant and lactating females.\n* Patients who receive immunosuppressive therapy.\n* Patients' refusal.\n* Patients with history or evidenced hypersensitivity to any component used in this study.",true,"18 Years","60 Years",{"count":68,"type":19},75,[70],"NA","This study aims to evaluate the efficacy and safety of intralesional injections of candida antigen, polidocanol sclerotherapy and combined candida antigen with polidocanol in treatment of patients with common warts.",[28],"NOT_YET_RECRUITING","2024-12-24",{"date":76,"type":48},"2024-12-27",{"date":78,"type":19},"2024-12-20",{"date":80,"type":19},"2025-12-01",{"name":82,"class":55},"Sohag University",1,{"id":85,"slug":86,"hasResults":11,"nctId":87,"briefTitle":88,"officialTitle":89,"acronym":90,"eligibilityCriteria":91,"healthyVolunteers":11,"sex":15,"minAge":92,"maxAge":4,"enrollmentInfo":93,"targetDuration":4,"studyType":20,"phases":95,"briefSummary":96,"conditions":97,"keywords":4,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":98,"lastUpdatePostDateStruct":99,"startDateStruct":101,"completionDateStruct":103,"leadSponsor":105,"locationsCount":108},"100360793","phase-4-randomized-placebo-controlled-double-blind-study-to-evaluate-the-efficacy-of-2lverujunior-and-2lveru-on-the-treatment-of-warts-100360793","NCT03977753","Randomized, Placebo-controlled, Double Blind Study to Evaluate the Efficacy of 2LVERU®JUNIOR and 2LVERU® on the Treatment of Warts","Study to Evaluate the Efficacy of 2LVERU® JUNIOR and 2LVERU® on the Treatment of Warts.","EVAsION","Inclusion Criteria:\n\n* Patients, male or female, aged 3 years and older,\n* Patients with common warts (Verruca vulgaris), and\u002For plantar warts (Verruca plantaris), and\u002For flat warts (Verruca plana),\n* Patients (and\u002For parents if necessary) having the faculties to understand and respect the constraints of the study,\n* Signature of the Informed Consent Form by the patient (and\u002For parents if necessary).\n\nExclusion Criteria:\n\n* Patients who have received any curative warts treatment in the previous 2 months prior to the study,\n* Patients who have received any homeopathic treatment in the previous 2 months prior to the study,\n* Patients under immunosuppressive treatment,\n* Patients having received immunotherapy or micro-immunotherapy during the last 6 months,\n* Patients with known lactose intolerance,\n* Pregnant or breastfeeding women,\n* Patients who participated in a clinical study in the previous 2-months period,\n* Patients (and\u002For parents of patients if necessary) who are not sufficiently motivated to engage on the total study follow-up period, or likely to travel or to move before the end of the study,\n* Patients with severe immunodeficiency disease requiring long term treatment (\\*) or patients under chemotherapy or radiotherapy,\n* Patients under listed homeopathic or phytotherapy treatment (see protocol),\n* Patients addicted to or using recreational drugs,\n* Patient under guardianship and\u002For curators, (\\*) important renal or respiratory insufficiency, transplanted or grafted patients, HIV\u002FAIDS, terminal cancer.","3 Years",{"count":94,"type":19},162,[22],"Human papillomavirus (HPV) infection is very common, as most people will experience infection during their lifetime. The most common manifestation of HPV infection is common warts. Common warts may appear at any age.\n\nConventional treatments can be used to treat warts and they are based on two mechanisms: stimulation of cellular immunity against HPVs or destruction of the lesion. These treatments are based on the location of the wart and the degree of the symptoms.\n\nNo specific antiviral therapy is available to cure warts and today, there is no treatment that allows the definitive eradication of the virus.\n\nThe 2LVERU® has been available for more than 20 years, and has received a marketing authorization in Belgium by the Federal Agency for Medicines and Health Products (FAMHP). It is used as an immune regulator in the treatment of common warts (verruca vulgaris), flat warts (verruca plana) or plantar warts (verruca plantaris) caused by Human Papillomavirus. Since 2LVERU® has been made available, clinical observational data collected on treated patients have shown the beneficial effect on the disappearance of warts.\n\nThe purpose of this placebo-controlled, randomized, double-blind trial is the comparison of the efficacy of the treatment on the disappearance of warts at the end of treatment (6-month visit) between the 2LVERU® JUNIOR and 2LVERU® versus the placebo group.",[28,29,26],"2024-10-29",{"date":100,"type":48},"2024-10-30",{"date":102,"type":48},"2020-02-17",{"date":104,"type":19},"2027-03-16",{"name":106,"class":107},"Labo'Life","INDUSTRY",18]